Brokerages Set Savara Inc (NASDAQ:SVRA) Price Target at $7.17

Shares of Savara Inc (NASDAQ:SVRA - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $7.17.

Several brokerages have commented on SVRA. Guggenheim reissued a "buy" rating and issued a $8.00 price objective (down from $9.00) on shares of Savara in a report on Wednesday, May 28th. Evercore ISI cut their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Wednesday, May 28th. Wells Fargo & Company reduced their price objective on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, May 28th. Finally, HC Wainwright lowered shares of Savara from a "buy" rating to a "neutral" rating and dropped their target price for the company from $6.00 to $2.00 in a research report on Thursday, May 29th.

Savara Stock Performance

NASDAQ SVRA traded up $0.08 during mid-day trading on Friday, reaching $2.48. 196,814 shares of the stock were exchanged, compared to its average volume of 1,420,944. Savara has a 1 year low of $1.89 and a 1 year high of $5.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The business's 50 day moving average is $2.90 and its 200-day moving average is $2.93. The company has a market capitalization of $429.33 million, a P/E ratio of -5.85 and a beta of 0.44.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). On average, equities research analysts forecast that Savara will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new stake in shares of Savara during the fourth quarter worth $33,000. XTX Topco Ltd acquired a new position in Savara during the fourth quarter worth about $34,000. Ameriprise Financial Inc. purchased a new stake in Savara during the 4th quarter valued at about $37,000. KLP Kapitalforvaltning AS acquired a new stake in Savara in the 4th quarter valued at about $41,000. Finally, Hsbc Holdings PLC purchased a new position in Savara in the 4th quarter worth approximately $48,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.